{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:01:27Z","timestamp":1789984887631,"version":"4.0.1"},"reference-count":56,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Allergic conjunctivitis is a prevalent, immune\u2010mediated hypersensitivity disorder of the ocular surface affecting 10%\u201320% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy. Despite its widespread impact, allergic conjunctivitis receives comparatively less clinical attention than other chronic allergic conditions. This review aims to assess the therapeutic potential and clinical efficacy of Reproxalap, a novel ophthalmic solution targeting reactive aldehyde species (RASP), for the treatment of allergic conjunctivitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review was conducted analyzing the pharmacological profile of Reproxalap and its clinical performance in phase 2 and phase 3 clinical trials. These trials evaluated the drug's safety, tolerability, and efficacy based on symptom relief, particularly ocular itching and inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Reproxalap demonstrated early\u2010onset and broad\u2010spectrum anti\u2010inflammatory activity through RASP inhibition. By trapping free aldehydes and modulating inflammatory mediators like cytokines and chemokines, it significantly reduced ocular inflammation. Clinical trial data indicated statistically significant improvement in itching scores and sustained symptom relief in patients with allergic conjunctivitis. The drug also showed a favorable safety profile, with minimal adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reproxalap represents a first\u2010in\u2010class RASP inhibitor with promising efficacy and safety for the treatment of allergic conjunctivitis. Its unique mechanism of action and encouraging clinical trial outcomes support its potential as a valuable therapeutic alternative that may improve patient outcomes and could also be applicable in other inflammatory ocular conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.72492","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:46:45Z","timestamp":1780289205000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reproxalap \u2010 A Novel Treatment Option for Allergic Conjunctivitis \u2013 A Comprehensive Narrative Review"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-9380","authenticated-orcid":false,"given":"Sanila","family":"Mughal","sequence":"first","affiliation":[{"name":"Department of Medicine Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2487-2915","authenticated-orcid":false,"given":"Roshanay Ejaz","family":"Awan","sequence":"additional","affiliation":[{"name":"Department of Medicine Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7753-4806","authenticated-orcid":false,"given":"Hur","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Medicine Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8001-541X","authenticated-orcid":false,"given":"Zahra","family":"Sania","sequence":"additional","affiliation":[{"name":"Department of Medicine, Women Medical and Dental College Khyber Medical University Pakistan Abbottabad Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5421-0212","authenticated-orcid":false,"given":"Ashna","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Medicine Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1320-8165","authenticated-orcid":false,"given":"Syeda Kaneez","family":"Sakina","sequence":"additional","affiliation":[{"name":"Department of Medicine Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1948-2812","authenticated-orcid":false,"given":"Amina","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Department of Medicine Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-9368","authenticated-orcid":false,"given":"Mohammed Mahmmoud Fadelallah","family":"Eljack","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Kassala Teaching Hospital, Kassala University of Bakht Alruda Ad Duwaym Kassala State Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"e_1_2_22_2_1","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v15i3.7456"},{"key":"e_1_2_22_3_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2020.11456"},{"key":"e_1_2_22_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050547"},{"key":"e_1_2_22_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.11.014"},{"key":"e_1_2_22_6_1","unstructured":"S.Baab P. H.Le B.Gurnani andE. E.Kinzer.Allergic Conjunctivitis. StatPearls [Internet](2024):3 Accessed June 14 2024 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448118\/."},{"key":"e_1_2_22_7_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.10.30"},{"key":"e_1_2_22_8_1","first-page":"5","article-title":"Allergic Conjunctivitis: Management","author":"Hamrah P.","year":"2024","journal-title":"UpToDate"},{"key":"e_1_2_22_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S441009"},{"key":"e_1_2_22_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1824-7288-39-18"},{"key":"e_1_2_22_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-0403-9"},{"key":"e_1_2_22_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-002-0061-7"},{"key":"e_1_2_22_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000676"},{"key":"e_1_2_22_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32830e6b3a"},{"key":"e_1_2_22_15_1","doi-asserted-by":"publisher","DOI":"10.33590\/emj\/1031271115"},{"key":"e_1_2_22_16_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780367812591-2216"},{"key":"e_1_2_22_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527692156"},{"key":"e_1_2_22_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502416"},{"key":"e_1_2_22_19_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2017.38.4003"},{"key":"e_1_2_22_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-019-0844-8"},{"key":"e_1_2_22_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.037"},{"key":"e_1_2_22_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13786"},{"key":"e_1_2_22_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.5679"},{"key":"e_1_2_22_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001421"},{"key":"e_1_2_22_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.01.011"},{"key":"e_1_2_22_26_1","unstructured":"Inxight Drugs. REPROXALAP. The National Center for Advancing Translational Sciences (NCATS) Accessed June 14 2024 https:\/\/drugs.ncats.io\/substances?q=%22reproxalap%22&facet=Substance%20Form%2FPrincipal%20Form."},{"key":"e_1_2_22_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0056"},{"key":"e_1_2_22_28_1","article-title":"A Randomized, Multi\u2010Center, Double\u2010Masked, Vehicle\u2010Controlled, Parallel\u2010Group Phase 2b Allergic Conjunctivitis Clinical Trial of Topical Ocular ADX\u2010102, a Novel Aldehyde Sequestering Agent","volume":"59","author":"Gomes P. J.","year":"2018","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"e_1_2_22_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.08.072"},{"key":"e_1_2_22_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101401"},{"key":"e_1_2_22_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2012.06.025"},{"key":"e_1_2_22_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx700235t"},{"key":"e_1_2_22_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312948"},{"key":"e_1_2_22_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(00)00226-4"},{"key":"e_1_2_22_35_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/493015"},{"key":"e_1_2_22_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24422"},{"issue":"11","key":"e_1_2_22_37_1","first-page":"3084","article-title":"Effect of Deferoxamine on Retinal Lipid Peroxidation in Experimental Uveitis","volume":"34","author":"Wu G. S.","year":"1993","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_22_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70297-5"},{"key":"e_1_2_22_39_1","doi-asserted-by":"publisher","DOI":"10.17925\/USOR.2023.17.1.31"},{"key":"e_1_2_22_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2007.09.010"},{"key":"e_1_2_22_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2012.05.005"},{"key":"e_1_2_22_42_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20111752"},{"key":"e_1_2_22_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315612745"},{"key":"e_1_2_22_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S345324"},{"key":"e_1_2_22_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00520-z"},{"key":"e_1_2_22_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.436"},{"key":"e_1_2_22_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.04.023"},{"issue":"7","key":"e_1_2_22_48_1","first-page":"3931","article-title":"The Aldehyde Trap NS2 Mitigates Dense Haze in a Rabbit Model of Photorefractive Keratectomy","volume":"56","author":"Gibson D. J.","year":"2015","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"e_1_2_22_49_1","first-page":"198","article-title":"ADX\u2010103, a Novel Small Molecule Aldehyde Sequestering Agent, Decreases Retinal Edema and Inflammation in a Rat Model of Diabetic Macular Edema","volume":"59","author":"Halilovic A.","year":"2018","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"e_1_2_22_50_1","article-title":"A Randomized, Comparator\u2010Controlled Phase 2 Clinical Trial of ADX\u2010102 Ophthalmic Solution in Noninfectious Anterior Uveitis","volume":"58","author":"Sheppard J. D.","year":"2017","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"e_1_2_22_51_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0087"},{"key":"e_1_2_22_52_1","unstructured":"E. J.Holland B.Cavanagh S. G.Machatha andT. C.BradyThe Novel RASP Modulator Reproxalap Rapidly Improves Signs and Symptoms of Dry Eye Disease: The TRANQUILITY Run\u2010In Cohort Accessed June 14 2024 https:\/\/www.aldeyra.com\/wp-content\/uploads\/2022\/07\/ASCRS22-TRANQUILITY-run-in-pres_23Apr22_-1.pdf."},{"key":"e_1_2_22_53_1","article-title":"Multi\u2010Center, Randomized, Double\u2010Masked, Parallel\u2010Group, Vehicle\u2010Controlled Phase 2b Dry Eye Disease Clinical Trial to Evaluate Safety and Efficacy of Topical Ocular Reproxalap, a Novel RASP Inhibitor","volume":"60","author":"Sheppard J. D.","year":"2019","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"e_1_2_22_54_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0087"},{"key":"e_1_2_22_55_1","unstructured":"Drugs.com.Reproxalap.;2023 Accessed June 14 2024 https:\/\/www.drugs.com\/nda\/reproxalap_230615.html."},{"key":"e_1_2_22_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S327691"},{"key":"e_1_2_22_57_1","unstructured":"Drugs.com. Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease.;2024 Accessed June 14 2024 https:\/\/www.drugs.com\/clinical_trials\/aldeyra-therapeutics-enrolls-first-patient-phase-3-clinical-trial-designed-enable-potential-21482.html."}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.72492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.72492","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.72492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:18:26Z","timestamp":1789982306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.72492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/hsr2.72492"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.72492","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"2025-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72492"}}